Rapamycin-loaded Immunoliposomes Functionalized wi... - BV FAPESP
Advanced search
Start date
Betweenand
Related content
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells

Full text
Author(s):
Eloy, Josimar O. ; Petrilli, Raquel ; Brueggemeier, Robert W. ; Marchetti, Juliana Maldonado ; Lee, Robert J.
Total Authors: 5
Document type: Journal article
Source: ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY; v. 17, n. 1, p. 48-56, 2017.
Web of Science Citations: 6
Abstract

Background: Liposomes have been employed to improve pharmacokinetics and reduce side effects of drugs. They can be functionalized with antibodies for targeted delivery. While the monoclonal antibody trastuzumab has been employed in the therapy of HER2-positive breast cancer, the resistance developed during treatment has been reported. Rapamycin could be used in combination with trastuzumab for improved therapeutic response. Objective: In this study, we aimed to develop rapamycin-loaded liposomes and immunoliposomes with trastuzumab, characterize them and evaluate their in vitro cytotoxicity. Method: Formulations were prepared by the thin film hydration method and immunoliposome was conjugated to antibody by covalent bond. Characterization involved particle size, polydispersity, zeta potential, encapsulation efficiency, functionalization efficiency, DSC and FTIR assays. Cell studies were conducted through the MTT assay. Results: SPC: Chol: DSPE-PEG formulation prepared at 1: 10 drug to lipid ratio presented high encapsulation efficiency, appropriate particle size, low polydispersity, negative zeta potential and colloidal stability. Rapamycin exhibited intermolecular interactions with lipids and underwent crystallinity reduction. Rapamycin-loaded immunoliposomes were prepared with high trastuzumab functionalization efficiency and antibody stability. Cytotoxicity studies showed that the HER2-positive SK-BR-3 cell line was sensitive to trastuzumab, either as free drug or in the context of immunoliposomes, and is more sensitive to rapamycin than the triple negative MDA-MB-231 cells. For MDA-MB-231, the liposomal rapamycin was more cytotoxic than the free drug. Furthermore, the immunoliposomes showed potent cytotoxicity against SK-BR-3 cells. Finally, rapamycin and trastuzumab exhibited in vitro synergistic effect, particularly through immunoliposomes. Conclusion: The formulation developed herein has potential for in vivo evaluation.. (AU)

FAPESP's process: 12/10388-3 - Liposomes and immunoliposomes containing anticancer drugs: development, characterization and efficacy evaluation against breast cancer
Grantee:Josimar de Oliveira Eloy
Support Opportunities: Scholarships in Brazil - Doctorate
FAPESP's process: 12/21513-3 - Strategies for paclitaxel and metformin vehiculation to improve breast cancer therapy: liposomes and dendrimers
Grantee:Juliana Maldonado Marchetti
Support Opportunities: Regular Research Grants
FAPESP's process: 13/05362-8 - Functionalization of liposomes containing metformin and paclitaxel with trastuzumab: development, characterization and evaluation of efficacy against breast cancer
Grantee:Josimar de Oliveira Eloy
Support Opportunities: Scholarships abroad - Research Internship - Doctorate